Nu Skin Enterprises : Q1 2021 Earnings Call Slides

Q1 2021

Important Information RegardingForward-LookingStatements:This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, product launches, customers and sales leaders, benefits to shareholders, strategies and initiatives; statements of management's expectations regarding the future status of the COVID-19 pandemic globally and across the company's markets, and government and public behavior in response to such status; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "continue," "anticipate," "project," "outlook," "guidance," "plan," "continue," "will," "would," "could," "may," "might," the

negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

• risk that epidemics, including the ongoingCOVID-19 pandemic, and other crises could negatively impact our business;
• adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
• risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
• any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
• political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
• uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
• risk offoreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
• uncertainties regarding the future financial performance of the businesses the company has acquired;
• risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventorywrite-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
• regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
• unpredictable economic conditions and events globally, including trade policies and tariffs;
• uncertainties related to interpretation of, and forthcoming regulations under, the 2017 U.S. tax reform legislation; the company's futuretax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
• continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this presentation to reflect any change except as required by law.

Q1 Results

Revenue +31% YOY; 5.7% fx impact

EPS $.91; +153% YOY

Sales Leaders +22%, Customers +34% YOY

	Manufacturing	Other
Japan		0%	Mainland
7%		China
	10%		22%

Southeast
Asia	10%	Revenue
		6%
		Distribution
		Hong Kong

Taiwan

12%

South Korea

22%

11%

Americas /

Pacific

EMEA

Customer / Sales Leader Performance

Market

Mainland China

Americas/Pacific

South Korea

S.E. Asia

Japan

HK/Taiwan

EMEA

Total

Sales Leaders (000s)

63 62 61

	Q1 2021		Q1 2020	YOY % Change
Customers		Sales Leaders	Customers		Sales Leaders	Customers		Sales Leaders
316,000		271,536		16,159	16%		3%
	16,716
407,413		12,340	214,139		6,930	90%		78%
152,390		7,099	174,004		6,608	(12%)		7%
152,889		6,882	145,116		6,634	5%		4%
126,525		6,131	119,784		5,635	6%		9%
66,042		3,501	66,024		3,348	--		5%
296,001		7,950	140,344		4,237	111%		88%
1,517,260		60,619	1,130,947		49,551	34%		22%
			Customers (000s)

1,500 1,5401,5571,517

	69	70
55	56	61	1,193	1,160	1,207	1,163	1,131
	50

Q1 2019

Q2 2019

Q3 2019

Q4 2019

Q1 2020

Q2 2020

Q3 2020

Q4 2020

Q1 2021

Q1 2019

Q2 2019

Q3 2019

Q4 2019

Q1 2020

Q2 2020

Q3 2020

Q4 2020

Q1 2021

Revenue by Segment (M)

Mainland China 9%

Americas / Pacific 100%

South Korea 7%

EMEA 115%

Japan 14%

Southeast Asia (3%)

Manufacturing 69%

Hong Kong / Taiwan 1%

Grov Tech (4225%)

Other (9%)

0.173

0.705

150

149

81

76

70

68

46

36

Q1'21

Q1'20

0

20

40

60

80

100

120

140

160